BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 19147582)

  • 1. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.
    Manié E; Vincent-Salomon A; Lehmann-Che J; Pierron G; Turpin E; Warcoin M; Gruel N; Lebigot I; Sastre-Garau X; Lidereau R; Remenieras A; Feunteun J; Delattre O; de Thé H; Stoppa-Lyonnet D; Stern MH
    Cancer Res; 2009 Jan; 69(2):663-71. PubMed ID: 19147582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
    Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
    Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
    Eachkoti R; Hussain I; Afroze D; Aejazaziz S; Jan M; Shah ZA; Das BC; Siddiqi MA
    Cancer Lett; 2007 Apr; 248(2):308-20. PubMed ID: 16996204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
    Birgisdottir V; Stefansson OA; Bodvarsdottir SK; Hilmarsdottir H; Jonasson JG; Eyfjord JE
    Breast Cancer Res; 2006; 8(4):R38. PubMed ID: 16846527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.
    Pinilla SM; Honrado E; Hardisson D; Benítez J; Palacios J
    Breast Cancer Res Treat; 2006 Sep; 99(1):85-90. PubMed ID: 16541313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan.
    Amikura T; Sekine M; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Nishino K; Haino K; Tanaka K;
    Gynecol Oncol; 2006 Feb; 100(2):365-71. PubMed ID: 16337994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity.
    Vincent-Salomon A; Gruel N; Lucchesi C; MacGrogan G; Dendale R; Sigal-Zafrani B; Longy M; Raynal V; Pierron G; de Mascarel I; Taris C; Stoppa-Lyonnet D; Pierga JY; Salmon R; Sastre-Garau X; Fourquet A; Delattre O; de Cremoux P; Aurias A
    Breast Cancer Res; 2007; 9(2):R24. PubMed ID: 17417968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.
    Quenneville LA; Phillips KA; Ozcelik H; Parkes RK; Knight JA; Goodwin PJ; Andrulis IL; O'Malley FP
    Cancer; 2002 Nov; 95(10):2068-75. PubMed ID: 12412159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas.
    Kleivi K; Diep CB; Pandis N; Heim S; Teixeira MR; Lothe RA
    J Pathol; 2005 Sep; 207(1):14-9. PubMed ID: 16007576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors.
    Krop I; Maguire P; Lahti-Domenici J; Lodeiro G; Richardson A; Johannsdottir HK; Nevanlinna H; Borg A; Gelman R; Barkardottir RB; Lindblom A; Polyak K
    Cancer Res; 2003 May; 63(9):2024-7. PubMed ID: 12727813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer.
    Ganesan S; Richardson AL; Wang ZC; Iglehart JD; Miron A; Feunteun J; Silver D; Livingston DM
    Cold Spring Harb Symp Quant Biol; 2005; 70():93-7. PubMed ID: 16869742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathology of BRCA1- and BRCA2-associated breast cancer.
    Honrado E; Benítez J; Palacios J
    Crit Rev Oncol Hematol; 2006 Jul; 59(1):27-39. PubMed ID: 16530420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
    Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
    Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.
    Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Gruvberger-Saal SK; Saal LH; Holm K; Hegardt C; Arason A; Fagerholm R; Persson C; Grabau D; Johnsson E; Lövgren K; Magnusson L; Heikkilä P; Agnarsson BA; Johannsson OT; Malmström P; Fernö M; Olsson H; Loman N; Nevanlinna H; Barkardottir RB; Borg Å
    Cancer Res; 2012 Aug; 72(16):4028-36. PubMed ID: 22706203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study.
    Rodríguez-Pinilla SM; Rodríguez-Gil Y; Moreno-Bueno G; Sarrió D; Martín-Guijarro Mdel C; Hernandez L; Palacios J
    Am J Surg Pathol; 2007 Apr; 31(4):501-8. PubMed ID: 17414096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.
    Aghmesheh M; Nesland JM; Kaern J; Dorum A; Edwards L; Byth K; Friedlander M; Jackson P; Tucker KM; Russell PJ
    Gynecol Oncol; 2004 Dec; 95(3):430-6. PubMed ID: 15581943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
    Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
    Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular pathology of hereditary breast cancer.
    Palacios J; Robles-Frías MJ; Castilla MA; López-García MA; Benítez J
    Pathobiology; 2008; 75(2):85-94. PubMed ID: 18544963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation.
    Salmon A; Amikam D; Sodha N; Davidson S; Basel-Vanagaite L; Eeles RA; Abeliovich D; Peretz T
    Clin Oncol (R Coll Radiol); 2007 Sep; 19(7):490-3. PubMed ID: 17572079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.